Share on Pinterest
Share with your friends


Cost of healthcare in the U.S.

Can drug spending keep growing?

screenshot_254POST SUMMARY: According to IMS, spending on medicines rose 13.1% on a nominal basis – and 10.3% on a real per capita basis – driven by innovation, higher levels of price increases and lower patent expiry impact. Will pharma continue this trend and is this a green light for more expensive drugs? Continue reading »

Biosimilars poised to make dent in branded Rx sales

bg_biosimilarPOST SUMMARY: Biosimilars are possible thanks to the Affordable Care Act and the law’s promise to bring cheaper versions of expensive biotech drugs to the U.S. market.  The biosimilar of Neupogen will save the U.S. health system more than $5.5 billion over the next decade, assuming a “conservative discount of 30 percent off the current brand price,” Express Scripts said Continue reading »

End the myths around DTC marketing

mythsEnough of myths, lies and propaganda that direct to consumer advertising drives consumers to ask for medications they don’t need and want.  In fact, DTC advertising educates, informs and helps patients choose the right treatments for their health needs. Continue reading »

The battle of high drug pricing is one that big pharma risks losing

ways-retirees-can-save-cost-prescription-drugs1Evidence of recent weeks suggests that the battle of high drug pricing is one that big pharma risks losing, raising questions over the economic model of an industry that relies heavily on US profits to reward investors and finance new drugs. Pharmaceutical executives say their ability to price drugs in the US, according to what the market will bear allows them to cover the considerable cost of finding new, often revolutionary, treatments; the cost of developing and winning approval for a new drug now runs at $2.6bn, according to the Tufts Center for the Study of Drug Development, compared with $802m in 2003. Continue reading »

Failure to take medications costs over $300 billion annually

Medical experts estimate that the failure to take prescription medications as directed costs some $300 billion a year in emergency room visits, in patient hospital care and extra visits to physicians offices.  If you think it’s all due to drug costs think again.  One study found that even in health plans where medications are free, rates of non-adherence were nearly 40%.  With the drug industry facing a huge loss of revenue from patent expiration you would figure that drug industry and the government would work to decrease non-adherence rates but they just can’t see the ROI clear enough. Continue reading »

No amount of innovation can justify the doubling of prices for cancer drugs

shutterstock_614148POST SUMMARY: The number of over-65s on the planet is projected almost to triple between 2010 and 2050 to 1.5bn, according to the UN. This, in turn, will spur a surge in age-related diseases such as cancer. The World Health Organization predicts the number of cases will increase 70 per cent in the next 20 years.  Global spending on cancer drugs has more than doubled in the past decade to $91bn in 2013, according to the IMS Institute for Healthcare Informatics. However, can the US healthcare system really afford $100,000 drugs?

Source: Financial Times “Counting the cost of cancer” Continue reading »

The assault on drug prices

cost-of-drugsPOST SUMMARY: According to an editorial in today’s Times “pharma companies are taking advantage of a mix of laws that force insurers to include essentially all expensive drugs in their policies, and a philosophy that demands that every new health care product be available to everyone, no matter how little it helps or how much it costs.”

Continue reading »